Investigating Novel Inflammatory Biomarkers and Pathways in Cardiac Cachexia

Area of Science:

• Cardiovascular Medicine
• Biomarker Discovery
• Proteomics

Background:

• Cardiac cachexia (CC) is a significant indicator of advanced heart failure (AHF), characterized by unintentional weight loss and poor prognosis.
• Current CC diagnosis involves inflammatory cytokine analysis; novel biomarkers are needed to understand underlying mechanisms.
• Proteomic analysis offers a pathway to identify new biomarkers and therapeutic targets for CC.

Purpose of the Study:

• To identify novel protein biomarkers and mechanistic pathways associated with cardiac cachexia (CC) in advanced heart failure (AHF).
• To explore the diagnostic potential of identified biomarkers using proteomic analysis.

Main Methods:

• Patients with AHF and CC/unintentional weight loss (UWL) were recruited.
• Plasma proteomic analysis was performed using the Olink Target 96 Cardiovascular II panel.
• Differential protein expression and pathway enrichment analyses were conducted, alongside receiver operator curve analysis for biomarker validation.

Main Results:

• Six proteins were differentially expressed in the CC/UWL group, including four novel biomarkers: interleukin-27, interleukin-4, vascular endothelial growth factor D, and bone morphogenetic protein-6.
• These novel proteins demonstrated suitability as biomarkers, with area under the receiver operator curve values ranging from 0.741 to 0.826.
• Pathway enrichment analysis identified significant roles for immune regulation and cytokine signaling in CC pathogenesis.

Conclusions:

• Four novel protein biomarkers for CC were identified, showing potential for disease identification.
• Proposed pathways involve immune regulation and cytokine signaling, warranting further investigation.
• Future research should focus on validating these biomarkers and exploring their therapeutic potential in CC.